_:b418228892 "2"^^ . _:b418228829 . _:b418228895 "2"^^ . _:b418228770 . _:b418228894 "2"^^ . . _:b6383269 . . . . _:b418228889 "2"^^ . _:b418228926 . . . . . _:b6383261 "within 3 months of XRT/daily TMZ completion; however, outcome among this subset did not differ compared to the remaining patients (data not shown) indicating that enrolment of patients with possible pseudoprogression (Brandes et al, >>2008<<; Brandsma et al, 2008) did not influence the outcome of this study. No patients had to discontinue study participation due to changing enzyme-inducing anti-epileptic drug (EIAED) status." . . _:b418228888 "2"^^ . _:b418228860 . . _:b418228879 . _:b418228891 "2"^^ . . _:b418228890 "2"^^ . . _:b418228901 "2"^^ . _:b418228780 . _:b418228900 "2"^^ . _:b418228903 "2"^^ . _:b418228850 . _:b418228917 . _:b418228902 "2"^^ . . _:b418228897 "2"^^ . . _:b418228896 "2"^^ . _:b418228831 . _:b418228741 . . . _:b418228883 . _:b418228899 "2"^^ . _:b418228898 "2"^^ . . _:b418228909 "2"^^ . _:b6383266 . . . _:b418228908 "2"^^ . _:b6383267 . . _:b418228911 "2"^^ . _:b418228795 . . _:b418228910 "2"^^ . . _:b418228905 "2"^^ . _:b6383270 . . _:b418228904 "2"^^ . . . _:b418228907 "2"^^ . _:b418228906 "2"^^ . _:b418228917 "2"^^ . _:b418228916 "2"^^ . _:b418228776 . . _:b418228919 "2"^^ . _:b6383272 . _:b418228784 . _:b418228847 . . _:b418228876 . . _:b418228918 "2"^^ . _:b418228791 . _:b418228730 . _:b418228913 "2"^^ . _:b418228912 "2"^^ . _:b418228744 . . _:b418228915 "2"^^ . . _:b418228914 "2"^^ . _:b418228865 . _:b418228908 . _:b418228925 "2"^^ . _:b418228833 . _:b418228924 "2"^^ . . . _:b418228927 "2"^^ . _:b418228822 . _:b418228741 . . _:b418228740 . _:b418228926 "2"^^ . _:b418228734 . _:b6383274 . _:b418228786 . _:b418228740 . _:b418228921 "2"^^ . . _:b418228754 . _:b418228743 . . . _:b418228732 . _:b418228920 "2"^^ . _:b418228742 . _:b418228733 . _:b418228734 . _:b418228735 . _:b418228728 . _:b418228923 "2"^^ . . _:b418228737 . _:b418228729 . _:b418228902 . _:b418228730 . _:b418228914 . _:b418228731 . . _:b418228724 . _:b418228922 "2"^^ . . _:b418228736 . . _:b418228725 . _:b418228726 . _:b418228727 . _:b418228739 . _:b418228933 "2"^^ . _:b418228889 . _:b418228721 . _:b418228722 . . _:b418228723 . . _:b418228932 "2"^^ . _:b418228738 . _:b418228749 . _:b418228748 . _:b418228751 . _:b418228929 "2"^^ . . _:b418228750 . _:b418228928 "2"^^ . _:b418228788 . _:b418228745 . _:b418228931 "2"^^ . _:b418228903 . _:b418228744 . _:b418228930 "2"^^ . . _:b418228800 . _:b418228747 . _:b418228737 . . _:b418228746 . . _:b418228739 . _:b418228757 . _:b418228756 . _:b6383260 . . _:b418228854 . . _:b418228759 . _:b6383261 . _:b418228758 . _:b6383262 . _:b418228897 . _:b418228725 . _:b418228753 . _:b6383263 . _:b6383260 "This rate is comparable to that previously reported in other multi-institutional studies (Stupp et al, 2005; Raymond et al, >>2008<<). The remaining patients had either grade 3 malignant glioma (n=11, 7.0%), grade 2 glioma (n=2, 1.3%), or were non-diagnostic (n=6, 3.8%). Most patients (88.7%) had just one measurable lesion at baseline. Only 11.7% of patients had" . . . . _:b418228752 . . _:b418228916 . _:b418228755 . . _:b418228754 . _:b6383258 . _:b418228825 . . . _:b418228840 . _:b418228815 . _:b418228765 . _:b6383259 . . _:b418228895 . _:b418228764 . _:b6383268 . _:b418228767 . _:b6383269 . _:b418228766 . _:b6383270 . _:b418228748 . _:b6383259 . _:b418228761 . _:b418228827 . _:b6383271 . _:b418228828 . . _:b418228760 . _:b6383264 . _:b418228763 . _:b6383265 . _:b418228817 . . _:b418228826 . . _:b418228881 . _:b418228857 . . _:b6383266 . _:b418228762 . _:b6383271 "patients and methods" . _:b418228782 . . _:b418228773 . _:b6383267 . . _:b418228772 . _:b418228816 . . _:b418228775 . _:b418228774 . . _:b418228783 . _:b418228769 . . . _:b418228768 . _:b6383272 . . _:b418228845 . _:b418228792 . _:b418228771 . _:b6383273 . . _:b418228770 . _:b6383274 . . _:b418228781 . _:b6383275 . . _:b418228729 . _:b418228780 . _:b418228866 . . _:b418228783 . _:b418228819 . . . _:b418228890 . _:b418228782 . _:b418228777 . _:b6383272 "The dose of imatinib differed between the trials to account for the effect of EIACDs on imatinib metabolism (Reardon et al, >>2005<<; Wen et al, 2006):" . _:b418228776 . . . _:b418228779 . . . _:b418228778 . . _:b418228807 . _:b418228743 . . . _:b418228789 . _:b418228796 . . _:b418228788 . _:b418228765 . . _:b418228791 . _:b418228812 . . _:b418228790 . _:b418228785 . . _:b418228928 . . _:b418228784 . _:b418228787 . . _:b418228786 . _:b418228797 . . _:b418228796 . _:b418228799 . _:b418228859 . . _:b418228775 . . _:b418228798 . _:b418228738 . _:b6383270 "However, to further investigate this potential association, we evaluated c-KIT copy number among patients with available archival tumour material who were treated on a previously published phase 2 study (Reardon et al, >>2005<<). Specifically, among 12 patients with adequate tumour material available for analysis, 3 had c-KIT polysomy or gene amplification. Although the differences did not reach statistical significance (P=0.15), the median PFS and PFS-6 were 16." . _:b418228793 . . _:b418228877 . _:b418228792 . _:b418228795 . . _:b418228789 . . . _:b418228794 . _:b418228813 . _:b418228805 . . _:b418228851 . _:b418228804 . _:b6383258 "results" . . _:b418228807 . _:b418228811 . _:b418228806 . . _:b418228888 . _:b418228861 . . . . . _:b418228801 . _:b418228800 . _:b418228803 . _:b418228802 . _:b418228797 . _:b418228912 . _:b418228813 . _:b6383268 . . . _:b418228812 . _:b418228753 . _:b418228815 . _:b418228814 . . _:b418228809 . _:b418228808 . _:b418228898 . . _:b418228811 . _:b418228798 . _:b418228830 . _:b418228892 . _:b418228810 . _:b418228838 . _:b6383267 "In contrast, none of the patients reported by Reardon et al (>>2005<<) discontinued therapy prematurely due to rapidly progressive tumour." . _:b418228821 . _:b418228834 . _:b418228820 . _:b418228823 . . _:b6383265 "Dresemann (>>2005<<) first reported that 6 of 30 patients (20%) achieved a radiographic response whereas 11 additional patients (37%) achieved SD for a median of 6 months (range 3\u201332 months)." . _:b418228822 . _:b418228817 . . . _:b418228816 . _:b418228893 . _:b418228819 . . . _:b418228869 . _:b418228818 . . _:b418228829 . . _:b418228828 . . _:b418228922 . _:b418228831 . . _:b418228874 . _:b418228830 . _:b418228901 . _:b418228825 . _:b418228824 . _:b418228821 . _:b418228827 . _:b418228803 . _:b418228826 . _:b418228820 . _:b418228823 . . _:b418228837 . _:b418228747 . . . _:b418228836 . . . _:b6383262 . _:b418228839 . _:b418228838 . . _:b418228929 . . _:b418228833 . . _:b418228832 . _:b418228777 . _:b418228781 . _:b418228835 . . _:b418228871 . _:b418228834 . _:b418228925 . _:b418228845 . _:b418228732 . . . _:b418228844 . _:b418228847 . . _:b418228846 . _:b6383273 . _:b418228790 . _:b418228841 . _:b418228769 . _:b418228840 . _:b418228741 "4"^^ . _:b418228733 . _:b418228843 . _:b6383273 "The dose of imatinib differed between the trials to account for the effect of EIACDs on imatinib metabolism (Reardon et al, 2005; Wen et al, >>2006<<): Patients enrolled on study H2201 received 600\u2009mg once a day, whereas those on study H2202 received 500\u2009mg twice a day. For both trials, patients received 500\u2009mg of HU twice a day. The studies were identical in all other respects." . . _:b418228740 "4"^^ . . _:b418228842 . . _:b418228814 . _:b418228743 "4"^^ . _:b418228853 . _:b418228742 "4"^^ . _:b418228852 . _:b418228751 . _:b418228910 . _:b418228737 "4"^^ . _:b418228855 . _:b418228736 "4"^^ . _:b418228774 . _:b418228854 . . _:b418228739 "4"^^ . _:b418228849 . _:b418228738 "4"^^ . _:b418228915 . _:b418228766 . _:b418228848 . _:b418228749 "4"^^ . _:b418228759 . _:b418228851 . _:b418228748 "4"^^ . . _:b418228850 . _:b418228751 "3"^^ . _:b418228805 . _:b418228861 . _:b418228756 . _:b418228750 "3"^^ . _:b418228761 . _:b418228860 . _:b418228745 "4"^^ . _:b418228863 . _:b418228744 "4"^^ . _:b418228862 . _:b418228747 "4"^^ . _:b6383269 "In preclinical GBM studies, PDGFR and CXCL12/SDF-1 expression are associated with imatinib sensitivity (Hagerstrand et al, >>2006<<). Although expression of CXCL12/SDF-1 was not assessed in this study, IHC expression of PDGFR did not correlate with PFS. However, we noted statistically increased PFS among two patients with either c-KIT gene amplification or polysomy" . _:b418228857 . _:b418228746 "4"^^ . _:b418228862 . . _:b418228856 . _:b418228907 . _:b418228757 "3"^^ . _:b418228722 . _:b418228859 . _:b418228756 "3"^^ . _:b6383261 . . _:b418228858 . . _:b418228839 . _:b6383259 "This rate is comparable to that previously reported in other multi-institutional studies (Stupp et al, >>2005<<; Raymond et al, 2008)." . _:b418228759 "3"^^ . _:b418228869 . _:b418228758 "3"^^ . _:b418228868 . _:b418228887 . _:b418228753 "3"^^ . . . _:b418228871 . _:b418228752 "3"^^ . _:b418228843 . _:b418228870 . _:b418228750 . _:b418228755 "3"^^ . _:b418228865 . _:b418228754 "3"^^ . _:b418228856 . _:b418228864 . _:b418228765 "3"^^ . _:b418228842 . _:b418228867 . . _:b418228764 "3"^^ . . _:b418228866 . _:b418228767 "3"^^ . _:b418228877 . . _:b418228766 "3"^^ . . . . _:b418228876 . _:b418228853 . _:b418228761 "3"^^ . _:b418228858 . _:b418228879 . _:b418228760 "3"^^ . _:b418228932 . _:b418228878 . . _:b418228763 "3"^^ . _:b418228873 . _:b418228762 "3"^^ . _:b418228872 . _:b418228773 "3"^^ . _:b418228875 . _:b418228727 . _:b418228772 "3"^^ . _:b418228844 . _:b418228874 . _:b418228779 . _:b418228775 "3"^^ . _:b418228863 . _:b418228885 . _:b418228774 "3"^^ . _:b418228918 . _:b418228884 . _:b418228769 "3"^^ . . . _:b418228887 . _:b418228905 . _:b418228768 "3"^^ . _:b418228764 . . _:b418228886 . _:b418228771 "3"^^ . _:b418228808 . . _:b418228881 . _:b418228770 "3"^^ . _:b418228848 . _:b6383260 . _:b418228880 . _:b418228781 "3"^^ . _:b418228883 . _:b418228780 "3"^^ . . _:b418228882 . _:b418228783 "3"^^ . _:b418228913 . _:b418228893 . _:b418228782 "3"^^ . _:b418228868 . _:b418228892 . . _:b418228777 "3"^^ . _:b6383265 . . _:b418228895 . _:b418228776 "3"^^ . _:b418228894 . _:b418228779 "3"^^ . _:b418228923 . . . _:b418228889 . _:b418228931 . _:b418228778 "3"^^ . _:b6383258 . _:b418228846 . _:b418228888 . _:b6383275 . _:b418228789 "3"^^ . _:b418228870 . _:b418228891 . _:b418228900 . _:b418228788 "3"^^ . . _:b418228890 . _:b418228791 "2"^^ . _:b418228901 . _:b418228790 "3"^^ . . _:b418228900 . _:b418228785 "3"^^ . _:b418228903 . . . _:b418228784 "3"^^ . . . _:b418228902 . _:b6383268 "Second, incorporation of rigorous independent, blinded, centralised outcome review with strict assessment guidelines in the current studies may have impacted the rates of determined response (Dodd et al, >>2008<<). In contrast, responses were assessed solely by study investigators in the prior single-centre studies." . _:b418228787 "3"^^ . _:b418228799 . _:b418228897 . _:b418228875 . _:b418228786 "3"^^ . _:b418228818 . . _:b418228896 . _:b418228797 "2"^^ . . _:b418228899 . _:b418228796 "2"^^ . _:b418228898 . _:b418228799 "2"^^ . _:b418228837 . _:b418228909 . _:b418228798 "2"^^ . . . _:b418228908 . _:b418228793 "2"^^ . _:b418228927 . . _:b418228806 . . _:b418228911 . _:b6383271 . _:b6383264 . . _:b418228792 "2"^^ . _:b418228910 . _:b418228795 "2"^^ . _:b418228801 . _:b418228758 . . _:b418228785 . . _:b418228841 . _:b418228905 . _:b418228886 . _:b418228794 "2"^^ . _:b418228904 . _:b418228805 "2"^^ . _:b418228899 . _:b418228907 . _:b418228748 . _:b418228804 "2"^^ . . _:b418228749 . _:b418228750 . _:b418228751 . _:b418228906 . _:b418228744 . _:b418228882 . _:b418228807 "2"^^ . _:b418228745 . _:b418228742 . _:b418228746 . _:b418228747 . _:b418228917 . _:b418228740 . _:b418228806 "2"^^ . _:b418228741 . _:b418228742 . _:b418228743 . _:b418228916 . _:b418228736 . _:b418228801 "2"^^ . _:b418228737 . _:b418228738 . . _:b418228919 . _:b418228739 . _:b418228800 "2"^^ . _:b418228764 . _:b418228765 . _:b418228766 . _:b418228767 . _:b418228918 . _:b418228760 . _:b418228803 "2"^^ . _:b418228761 . _:b418228762 . _:b418228763 . _:b418228913 . _:b418228756 . _:b418228802 "2"^^ . _:b418228757 . _:b418228758 . _:b418228759 . _:b418228912 . _:b418228752 . _:b418228813 "2"^^ . _:b418228753 . _:b418228754 . _:b418228755 . _:b418228915 . _:b418228731 . _:b418228812 "2"^^ . _:b418228780 . _:b418228781 . _:b418228782 . _:b418228873 . _:b418228783 . _:b418228914 . . _:b418228776 . _:b418228815 "2"^^ . _:b418228777 . _:b418228778 . _:b418228849 . _:b418228779 . _:b418228925 . _:b418228772 . _:b418228814 "2"^^ . _:b418228773 . _:b418228774 . _:b418228775 . _:b418228924 . _:b418228919 . _:b418228768 . _:b418228809 "2"^^ . . _:b418228769 . . _:b6383258 _:b6383260 . _:b418228770 . _:b6383258 _:b6383261 . _:b418228927 . _:b418228771 . _:b6383258 _:b6383262 . _:b418228808 "2"^^ . _:b418228796 . _:b6383258 _:b6383263 . _:b418228797 . _:b418228798 . _:b418228787 . . _:b418228926 . _:b418228799 . _:b418228792 . _:b418228811 "2"^^ . _:b6383258 _:b6383259 . _:b418228793 . _:b418228794 . _:b418228795 . _:b418228921 . _:b418228788 . _:b418228810 "2"^^ . _:b418228789 . _:b418228804 . _:b418228790 . _:b418228791 . _:b418228920 . _:b418228784 . _:b418228821 "2"^^ . _:b418228785 . _:b418228786 . _:b418228787 . _:b418228923 . . "10.1038%2Fsj.bjc.6605411" . _:b418228812 . _:b418228820 "2"^^ . _:b418228813 . _:b418228814 . _:b418228815 . _:b418228922 . _:b418228808 . _:b418228823 "2"^^ . _:b418228809 . _:b418228810 . _:b418228811 . _:b418228933 . . _:b418228822 "2"^^ . _:b418228809 . _:b418228804 . _:b418228805 . _:b418228806 . _:b418228807 . _:b418228932 . _:b418228800 . _:b418228817 "2"^^ . _:b418228801 . . _:b418228802 . _:b418228803 . _:b418228828 . _:b418228816 "2"^^ . _:b418228829 . _:b418228830 . _:b418228831 . . _:b418228819 "2"^^ . . _:b418228824 . . . _:b418228825 . . _:b418228826 . . _:b418228929 . _:b418228880 . _:b418228855 . . _:b418228827 . _:b418228820 . _:b418228818 "2"^^ . _:b418228821 . . _:b418228822 . _:b418228823 . _:b418228928 . _:b418228816 . _:b418228829 "2"^^ . _:b418228817 . _:b418228818 . . _:b418228931 . _:b418228819 . _:b418228844 . _:b418228828 "2"^^ . _:b418228845 . _:b418228755 . _:b418228846 . . _:b418228930 . _:b418228847 . _:b418228840 . _:b418228831 "2"^^ . _:b418228728 . _:b418228841 . _:b418228842 . . _:b418228911 . _:b418228843 . . _:b418228836 . _:b418228830 "2"^^ . _:b418228837 . _:b418228725 . _:b418228838 . _:b418228839 . _:b418228832 . _:b418228825 "2"^^ . _:b418228833 . _:b418228724 . _:b418228834 . . _:b418228835 . _:b418228860 . _:b418228824 "2"^^ . _:b418228861 . _:b418228727 . _:b418228862 . _:b418228863 . _:b418228856 . _:b418228827 "2"^^ . _:b418228857 . _:b418228726 . _:b418228858 . _:b418228859 . . _:b418228826 "2"^^ . _:b418228852 . _:b418228853 . _:b418228721 . _:b418228854 . _:b418228855 . _:b418228848 . _:b418228837 "2"^^ . _:b418228849 . _:b418228850 . _:b418228920 . _:b418228851 . _:b418228876 . _:b418228836 "2"^^ . _:b418228767 . _:b418228877 . . _:b418228878 . _:b418228723 . _:b418228879 . _:b418228872 . _:b418228839 "2"^^ . _:b418228873 . _:b418228722 . _:b418228874 . _:b418228875 . _:b418228868 . _:b418228838 "2"^^ . _:b418228869 . _:b418228733 . _:b418228870 . _:b418228871 . _:b418228810 . . _:b418228896 . _:b418228833 "2"^^ . _:b418228864 . . _:b418228865 . _:b418228793 . _:b418228866 . _:b418228732 . _:b418228867 . _:b418228892 . _:b418228832 "2"^^ . . _:b418228893 . _:b418228735 . _:b418228894 . _:b418228895 . _:b418228888 . _:b418228924 . _:b418228835 "2"^^ . _:b418228889 . . _:b418228734 . _:b418228890 . _:b418228891 . _:b418228884 . _:b418228834 "2"^^ . _:b418228885 . _:b418228729 . _:b418228933 . "PMC0" . _:b418228886 . _:b418228772 . _:b418228887 . _:b418228880 . _:b418228845 "2"^^ . _:b418228881 . _:b418228728 . _:b418228882 . . _:b418228883 . _:b418228908 . _:b418228844 "2"^^ . _:b418228909 . _:b418228731 . _:b418228910 . _:b418228911 . _:b418228904 . _:b418228847 "2"^^ . _:b418228905 . _:b6383264 "discussion" . _:b418228906 . _:b418228730 . _:b418228907 . _:b418228900 . _:b418228904 . _:b418228846 "2"^^ . _:b418228901 . _:b418228835 . _:b418228902 . _:b418228903 . _:b418228896 . _:b418228841 "2"^^ . _:b418228897 . _:b418228898 . _:b418228899 . _:b418228924 . _:b418228840 "2"^^ . _:b418228925 . . . _:b418228926 . . _:b418228927 . _:b418228721 . _:b418228843 "2"^^ . _:b418228920 . . _:b418228921 . _:b418228724 . _:b418228922 . _:b418228760 . _:b418228923 . _:b418228916 . _:b418228842 "2"^^ . _:b418228917 . _:b418228918 . _:b418228919 . _:b418228912 . _:b418228853 "2"^^ . _:b418228913 . _:b418228914 . _:b418228909 . . _:b418228915 . _:b418228852 "2"^^ . _:b418228752 . _:b418228855 "2"^^ . _:b418228824 . _:b418228878 . _:b418228932 . _:b418228854 "2"^^ . _:b418228933 . _:b418228726 . _:b418228906 . _:b418228928 . _:b418228849 "2"^^ . _:b418228929 . . _:b418228930 . _:b418228757 . _:b418228931 . _:b418228736 . _:b418228848 "2"^^ . _:b418228832 . _:b418228851 "2"^^ . _:b418228771 . _:b418228746 . . _:b418228850 "2"^^ . . . _:b418228872 . . _:b418228861 "2"^^ . _:b6383264 _:b6383268 . _:b418228836 . . _:b418228864 . _:b6383264 _:b6383269 . _:b6383264 _:b6383270 . _:b418228860 "2"^^ . _:b6383264 _:b6383265 . _:b6383264 _:b6383266 . _:b418228863 "2"^^ . _:b6383264 _:b6383267 . _:b418228862 "2"^^ . _:b418228778 . _:b418228857 "2"^^ . _:b418228921 . _:b418228724 "6"^^ . _:b6383271 _:b6383272 . _:b6383271 _:b6383273 . _:b418228723 . _:b418228930 . _:b418228856 "2"^^ . _:b418228727 "5"^^ . _:b6383271 _:b6383274 . _:b418228794 . _:b6383271 _:b6383275 . _:b418228725 "6"^^ . _:b6383262 "TMZ completion; however, outcome among this subset did not differ compared to the remaining patients (data not shown) indicating that enrolment of patients with possible pseudoprogression (Brandes et al, 2008; Brandsma et al, >>2008<<) did not influence the outcome of this study. No patients had to discontinue study participation due to changing enzyme-inducing anti-epileptic drug (EIAED) status." . _:b418228726 "5"^^ . _:b418228859 "2"^^ . _:b418228722 "6"^^ . _:b418228858 "2"^^ . _:b418228723 "6"^^ . _:b418228891 . . . _:b418228749 . _:b418228869 "2"^^ . _:b418228721 "10"^^ . _:b418228868 "2"^^ . _:b418228884 . _:b418228871 "2"^^ . _:b418228733 "4"^^ . _:b418228870 "2"^^ . . . _:b418228732 "4"^^ . . _:b418228865 "2"^^ . _:b418228735 "4"^^ . _:b418228864 "2"^^ . _:b6383263 . _:b418228734 "4"^^ . _:b418228867 "2"^^ . . _:b418228729 "5"^^ . _:b418228866 "2"^^ . . . _:b418228877 "2"^^ . _:b418228728 "5"^^ . _:b418228852 . . _:b418228731 "4"^^ . _:b418228876 "2"^^ . _:b6383275 "Wong et al (>>1999<<) previously reported a 5% radiographic response rate among patients with GBM treated with TMZ at first recurrence." . _:b418228730 "5"^^ . _:b418228879 "2"^^ . _:b418228768 . _:b418228878 "2"^^ . . _:b418228873 "2"^^ . . _:b418228872 "2"^^ . . . . _:b418228875 "2"^^ . _:b418228867 . . _:b418228874 "2"^^ . . . _:b418228885 "2"^^ . _:b6383263 "Overall, imatinib, CGP74588, and HU pharmacokinetic results were consistent with those previously reported and confirm the marked impact of EIAEDs on imatinib metabolism (Table 3; Reardon et al, >>2005<<). Specifically, dose-normalised Cmax and AUCs of imatinib were lowered for patients on EIAEDs compared with those who were not on EIAEDs. Slight elevations of CGP74588 compared with parent drug ratio were noted for patients on EIAEDs" . _:b6383274 "Disease status was assessed using a modified version of the Macdonald criteria (Macdonald et al, >>1990<<), including an increase in corticosteroid dosing, regardless of radiographic or clinical assessment, as a criteria to define progressive disease (PD)." . _:b418228884 "2"^^ . . _:b418228887 "2"^^ . _:b418228762 . _:b418228886 "2"^^ . _:b418228773 . _:b418228881 "2"^^ . . . _:b418228880 "2"^^ . . _:b418228894 . _:b418228802 . _:b418228745 . . _:b418228883 "2"^^ . _:b418228763 . . _:b418228882 "2"^^ . _:b418228893 "2"^^ . _:b418228885 . _:b418228735 . _:b6383266 "In a follow-up phase II study among 33 patients, Reardon et al (>>2005<<) noted a radiographic response rate of 9% and PFS-6 of 27%." . . .